Predictive biomarkers for bevacizumab are required for selecting patients with high-grade ovarian cancer who will respond to bevacizumab in the first-line (1L) setting. Poor tumor intrinsic sensitivity was a predictive factor of bevacizumab in the ICON-7 trial (NCT00483782), characterized by the modeled CA-125 kinetic parameter (KELIM). The Phase III double-blind, placebo-controlled trial, GOG-0218 (NCT00262847) evaluated carboplatin and paclitaxel with or without bevacizumab in patients with stage III or stage IV ovarian, epithelial, primary peritoneal, or fallopian tube cancer. Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, talks about an external validation in GOG-0218 trial, assessing the association of the KELIM score and efficacy of bevacizumab for progression-free survival (PFS) and overall-survival (OS). Patients who showed benefit from bevacizumab versus placebo showed unfavorable KELIM, whilst those with favorable KELIM showed no benefit, confirming the results of the ICON-7 trial. These results further indicates patients who derive benefit from bevacizumab are poorly chemosensitive. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
